Recent Updates
Recently added Catalysts
RGNX Positive Sentiment Score: 65/100

REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference

Tuesday, August 1, 2023 1 min read
Key Takeaway: REGENXBIO Inc. announced its participation in the 2023 Wedbush PacGrow Healthcare Conference, which is set for August 8, 2023. The company will host one-on-one meetings with investors during the event. REGENXBIO focuses on gene therapy, utilizing its proprietary NAV Technology Platform to develop various therapeutic candidates. The company aims to progress five AAV Therapeutics into pivotal-stage or commercial products by 2025 as part of its growth strategy.

Market Sentiment Analysis

POSITIVE FACTORS

  • REGENXBIO is actively engaging with investors, indicating confidence in its future.
  • The company highlights its innovative NAV Technology Platform for gene therapy.
  • It has a clear strategy ('5x'25') aimed at advancing multiple therapeutic products.

Full Press Release Details

ROCKVILLE, Md., Aug. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, June 8, 2023.
2023 Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 8, 2023
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from its internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
SOURCE REGENXBIO Inc.

21 %

more press release views with

Frequently Asked Questions

What event will REGENXBIO host on August 8, 2023?

REGENXBIO will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference.

What is the focus of REGENXBIO Inc.?

REGENXBIO focuses on gene therapy to enhance lives using its NAV Technology Platform.

What does the NAV Technology Platform include?

It includes exclusive rights to over 100 novel adeno-associated virus vectors.

What is the '5x'25' strategy of REGENXBIO?

The strategy aims to advance five AAV Therapeutics to pivotal or commercial stages by 2025.

What types of programs is REGENXBIO developing?

REGENXBIO is developing a pipeline in various therapeutic areas, including late-stage programs.

Tags: RGNX Viatris Investor Conferences Healthcare REGENXBIO gene therapy AAV Technology investor meetings healthcare conference
Last updated: Aug 1, 2023